@joshua/hard-clinical-reasoning-cases
Advanced clinical reasoning cases
Author-made · not reviewedInternal medicineCC BY 4.0
Written by the BenchClub team with AI help: advanced multi-step cases across 13 specialties, graded on strict scoring points with penalties for dangerous errors. Answers follow public guidelines and drug labels; not yet reviewed by a practising physician.
v120 questionsUpdated Nov 18, 2026
- HCR-001Short answerEndocrinologyAdvanced
A 54-year-old man (80 kg) with type 2 diabetes on metformin and empagliflozin is on day 2 after a laparoscopic cholecystectomy. He has been kept nil by mouth and now has nausea, vomiting and deep, rapid breathing. Glucose 196 mg/dL, venous pH 7.08, bicarbonate 7 mEq/L, anion gap 26, beta-hydroxybutyrate 6.1 mmol/L, potassium 3.2 mEq/L, sodium 136 mEq/L, creatinine 1.3 mg/dL (baseline 0.9), lactate 1.4 mmol/L. Your hospital follows the 2024 ADA/EASD/JBDS/AACE/DTS hyperglycemic crises consensus report. What is your plan?
Rubric
- +2Identifies euglycemic DKA precipitated by the SGLT2 inhibitor with fasting/surgery and stops empagliflozin
- +3Delays insulin until potassium is at least 3.5 mEq/L, giving IV potassium about 10–20 mEq/h meanwhile
- +2Then starts IV insulin at about 0.1 unit/kg/h (about 8 units/h)
- +3Adds dextrose-containing fluid (D5/D10) from the start of insulin because glucose is below 250 mg/dL, so insulin can continue until ketoacidosis resolves (rate 0.05–0.1 unit/kg/h)
- +2Defines resolution by ketones and acid-base (beta-hydroxybutyrate < 0.6 mmol/L and pH ≥ 7.3 or bicarbonate ≥ 18 mEq/L), not by glucose
- +1Starts isotonic crystalloid (about 1 L in the first hour)
- -3Gives sodium bicarbonate at pH 7.08
- -3Starts insulin while potassium is 3.2 mEq/L
Show answer
Reference answer This is euglycemic DKA (glucose < 250 mg/dL) precipitated by the SGLT2 inhibitor plus fasting and surgery. Stop empagliflozin, and hold metformin given the AKI and acidosis. Start isotonic crystalloid (balanced solution or 0.9% saline, about 1 L in the first hour, then guided by volume status). Potassium is 3.2, below the 2024 consensus threshold of 3.5 mEq/L, so insulin is delayed while IV potassium is given at about 10–20 mEq/h; once K ≥ 3.5, start a fixed-rate IV insulin infusion at 0.1 unit/kg/h (8 units/h), keeping K 4–5 mEq/L with potassium in the fluids. Because glucose is already < 250 mg/dL, add dextrose (D5 or D10) from the start of insulin so that insulin (0.1 unit/kg/h, or reduced to about 0.05 unit/kg/h) can continue until the ketoacidosis clears. Bicarbonate is not indicated (pH ≥ 7.0). Monitor glucose hourly and ketones, electrolytes and venous pH every 2–4 h. DKA has resolved when beta-hydroxybutyrate is < 0.6 mmol/L and venous pH ≥ 7.3 or bicarbonate ≥ 18 mEq/L; glucose is not a resolution criterion. Do not restart the SGLT2 inhibitor until he is eating and fully recovered.
Source Umpierrez GE et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report (ADA/EASD/JBDS/AACE/DTS), Diabetes Care 2024
- HCR-002Short answerToxicologyAdvanced
A 45-year-old man (70 kg) is brought in drowsy after a weekend of heavy drinking. He complains his vision is blurred, "like being in a snowstorm", and fundoscopy shows hyperemic optic discs. Labs: sodium 140 mEq/L, chloride 100 mEq/L, bicarbonate 9 mEq/L, glucose 108 mg/dL, BUN 14 mg/dL, ethanol 92 mg/dL, measured serum osmolality 368 mOsm/kg, arterial pH 7.12, lactate 2.1 mmol/L, creatinine 1.0 mg/dL. A methanol level is a send-out test that will take 2 days; fomepizole and hemodialysis are available. What is going on, and what do you do?
Rubric
- +2Includes ethanol in the calculated osmolality and still finds a clearly elevated osmolar gap (about 50–80 mOsm/kg depending on the formula)
- +2Concludes methanol poisoning from the high anion gap, residual osmolar gap and visual findings
- +2Gives fomepizole 15 mg/kg IV loading dose (about 1,050 mg) followed by 10 mg/kg every 12 h
- +2States that fomepizole must be given more often during hemodialysis (every 4 h, or as a continuous infusion)
- +3Starts urgent hemodialysis because of visual impairment and severe acidosis without waiting for a methanol level
- +1Gives folic acid or folinic acid (leucovorin) as cofactor therapy
- -3Concludes the osmolar gap or the acidosis is explained by ethanol or alcoholic ketoacidosis and withholds fomepizole
Show answer
Reference answer Anion gap = 140 − (100 + 9) = 31, a severe high-anion-gap metabolic acidosis not explained by lactate. Calculated osmolality must include ethanol: 2(140) + 108/18 + 14/2.8 + 92/3.7 ≈ 280 + 6 + 5 + 25 ≈ 316 mOsm/kg, so the osmolar gap is about 52 mOsm/kg even after ethanol is accounted for (other accepted formulas give up to about 77). With the visual findings this is methanol poisoning; the ethanol does not explain the gap or the acidosis. Give fomepizole 15 mg/kg IV (1,050 mg), then 10 mg/kg every 12 h (15 mg/kg after 48 h); during hemodialysis the dosing interval shortens to every 4 h (or a continuous infusion is used). Start intermittent hemodialysis urgently: EXTRIP recommends it for new visual impairment, pH ≤ 7.15 or anion gap > 24, without waiting for a methanol level. Give folic acid or folinic acid (leucovorin) 50 mg IV every 6 h as cofactor, and IV sodium bicarbonate to correct the acidemia.
Source EXTRIP Workgroup recommendations for methanol poisoning (Roberts DM et al., Crit Care Med 2015); American Academy of Clinical Toxicology practice guideline on methanol poisoning (Barceloux DG et al., 2002); fomepizole US prescribing information
- HCR-003Short answerHematologyAdvanced
A 66-year-old woman (68 kg) with Child-Pugh class B alcohol-related cirrhosis (bilirubin 3.4 mg/dL, albumin 2.8 g/dL, INR 1.5) has been in hospital for 8 days. She received enoxaparin prophylaxis from admission. On day 6 a left femoral DVT was found; she was switched to an IV unfractionated heparin infusion, and warfarin 5 mg was started yesterday. Today her platelet count is 74 × 10^9/L (240 on admission, 190 on day 5). Creatinine clearance is 85 mL/min. A PF4/heparin ELISA returns strongly positive (OD 2.1). What do you do with her anticoagulation?
Rubric
- +2Stops all heparin, including flushes and heparin-coated catheters
- +3Stops warfarin and reverses it with vitamin K, citing the risk of venous limb gangrene
- +3Chooses a non-heparin anticoagulant suited to Child-Pugh B cirrhosis: fondaparinux (about 7.5 mg daily) or bivalirudin, or argatroban only at a reduced start (about 0.5 mcg/kg/min)
- +1Uses therapeutic, not prophylactic, intensity because of the DVT
- +1If warfarin is resumed later, starts it only after platelets are at least 150 × 10^9/L with at least 5 days of overlap (or keeps fondaparinux)
- -3Starts argatroban at the standard 2 mcg/kg/min
- -3Uses rivaroxaban despite Child-Pugh B cirrhosis
- -2Gives prophylactic platelet transfusion
Show answer
Reference answer This is HIT with thrombosis (high 4Ts score: > 50% fall starting around days 5–10, new DVT, strongly positive ELISA). Stop all heparin, including flushes and heparin-coated lines. Stop warfarin and give vitamin K (e.g., 5–10 mg orally or IV): warfarin started in acute HIT depletes protein C and can cause venous limb gangrene. She needs a therapeutic-intensity non-heparin anticoagulant chosen for her liver disease: fondaparinux (7.5 mg SC daily for 50–100 kg; her CrCl is fine) or bivalirudin are suitable. Argatroban is hepatically cleared; in moderate hepatic impairment it must start at a much lower dose (0.5 mcg/kg/min) with careful aPTT titration. Rivaroxaban should be avoided in Child-Pugh B (US label), and apixaban has no dose recommendation and little data in Child-Pugh B with cirrhotic coagulopathy, so it is not the first choice here. Do not give prophylactic platelet transfusions. If she is later transitioned to warfarin, start it only after platelets have recovered to ≥ 150 × 10^9/L, at a low dose, overlapping for at least 5 days and until the INR is in range; continuing fondaparinux is a reasonable alternative given unreliable INR monitoring in cirrhosis.
Source ASH 2018 Guidelines for Management of Venous Thromboembolism: Heparin-Induced Thrombocytopenia (Cuker A et al., Blood Adv 2018); argatroban and rivaroxaban US prescribing information
- HCR-004Multiple choiceNephrologyAdvanced
A 61-year-old man with decompensated cirrhosis has had several days of vomiting and has been taking furosemide. Arterial gas: pH 7.52, PaCO2 28 mm Hg, bicarbonate 22 mEq/L. Sodium 134 mEq/L, chloride 100 mEq/L, albumin 1.6 g/dL, lactate 4.1 mmol/L. The laboratory's reference range for the anion gap is 8–12 mEq/L at normal albumin (4.0 g/dL). Which description of his acid-base status is correct?
- AAcute respiratory alkalosis with appropriate metabolic compensation only
- BRespiratory alkalosis with a normal-anion-gap metabolic acidosis
- CRespiratory alkalosis with a high-anion-gap metabolic acidosis only
- DMetabolic alkalosis with respiratory alkalosis, no metabolic acidosis
- ERespiratory alkalosis, high-anion-gap metabolic acidosis and metabolic alkalosis
Show answer
Answer E
Source Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine (Clin J Am Soc Nephrol 2007); Figge J et al. albumin correction of the anion gap (Crit Care Med 1998); Berend K et al. Physiological approach to assessment of acid-base disturbances (N Engl J Med 2014)
- HCR-005Short answerOncologyAdvanced
A 24-year-old man (70 kg, body surface area 1.9 m²) with osteosarcoma received high-dose methotrexate 12 g/m² over 4 hours with hydration, urine alkalinization and leucovorin rescue starting at 24 hours. He takes omeprazole for reflux. Glucarpidase is stocked in your hospital. At 42 hours after the start of the infusion his methotrexate level is 38 µmol/L, creatinine has risen from 0.8 to 2.6 mg/dL, and urine output is falling. He has mild mucositis. What do you do now?
Rubric
- +3Gives glucarpidase 50 units/kg IV now, recognizing the 42-h level with AKI meets the threshold
- +3States leucovorin must not be given within 2 hours before or after glucarpidase
- +2Continues high-dose leucovorin for at least 48 h after glucarpidase, at the dose based on the pre-glucarpidase methotrexate level
- +2States post-glucarpidase methotrexate levels need a chromatographic assay because immunoassays cross-react with DAMPA
- +1Stops omeprazole and other drugs that delay methotrexate clearance (e.g., NSAIDs, penicillins)
- +1Continues IV hydration with urine alkalinization to urine pH ≥ 7, watching fluid balance as urine output falls
- -3Stops leucovorin once glucarpidase has been given
- -2Chooses hemodialysis as the main way to remove methotrexate instead of glucarpidase
Show answer
Reference answer He has delayed methotrexate clearance with methotrexate-induced AKI, and a 42-hour level of 38 µmol/L is far above the consensus threshold for glucarpidase (about 10 µmol/L at 42 h). Give glucarpidase 50 units/kg IV over 5 minutes (3,500 units) as soon as possible (ideally within 48–60 h). Leucovorin is itself a glucarpidase substrate: do not give leucovorin within 2 hours before or after glucarpidase. Continue high-dose leucovorin afterwards, for the first 48 hours at the dose based on the pre-glucarpidase methotrexate level (glucarpidase does not remove intracellular methotrexate), and then guided by chromatographic levels until methotrexate is below about 0.05–0.1 µmol/L. For 48 hours after glucarpidase, measure methotrexate with a chromatographic method: immunoassays cross-react with the metabolite DAMPA and overestimate the level. Continue IV hydration with urine alkalinization (urine pH ≥ 7), and stop drugs that reduce methotrexate clearance (omeprazole and other PPIs, NSAIDs, penicillins, probenecid). Glucarpidase, not hemodialysis, is the preferred way to lower methotrexate.
Source Ramsey LB et al. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance, The Oncologist 2018; glucarpidase (Voraxaze) US prescribing information
- HCR-006Short answerInfectious diseaseAdvanced
A 34-year-old man (60 kg) with newly diagnosed HIV (CD4 42 cells/µL, not yet on ART) has had 10 days of worsening headache and vomiting. He is alert with no focal deficits. Lumbar puncture: opening pressure 34 cm H2O, CSF cryptococcal antigen positive, India ink positive. Creatinine is normal. Liposomal amphotericin B, flucytosine and fluconazole are all available, and your unit follows the WHO 2022 guideline. Write his plan for the next 6 weeks.
Rubric
- +3Gives single-dose liposomal amphotericin B 10 mg/kg (about 600 mg) with flucytosine 100 mg/kg/day and fluconazole 1,200 mg/day for 14 days
- +2Performs therapeutic lumbar punctures to lower the pressure (by about 50% or below 20 cm H2O) and repeats them daily while raised
- +3Delays ART until 4–6 weeks after starting antifungal therapy
- +1Gives saline prehydration and potassium/magnesium supplementation with amphotericin
- +1Follows with fluconazole 800 mg/day consolidation for 8 weeks
- -3Gives corticosteroids such as dexamethasone
- -2Uses acetazolamide or mannitol to lower the pressure
- -3Starts ART within the first 2 weeks
Show answer
Reference answer Cryptococcal meningitis with raised intracranial pressure. WHO 2022 preferred induction: a single dose of liposomal amphotericin B 10 mg/kg (600 mg) on day 1, plus flucytosine 100 mg/kg/day in four divided doses and fluconazole 1,200 mg/day, both for 14 days. Then consolidation with fluconazole 800 mg/day for 8 weeks and maintenance 200 mg/day. Give saline prehydration and potassium and magnesium supplementation with amphotericin, and monitor renal function, electrolytes and blood counts. Treat the raised pressure with therapeutic lumbar punctures, removing CSF to bring the pressure down by about 50% or below 20 cm H2O, repeated daily while it stays high or symptoms persist. Do not use corticosteroids, acetazolamide or mannitol. Start ART 4–6 weeks after starting antifungal treatment; early ART increases mortality in cryptococcal meningitis.
Source WHO Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV (2022)
- HCR-007Short answerObstetricsAdvanced
A 31-year-old G1 at 38 weeks with preeclampsia with severe features is on a magnesium sulfate infusion and oral nifedipine. She has severe persistent asthma (intubated for an exacerbation 2 years ago, ED visit for wheeze last month). Twenty minutes after a vaginal delivery she has lost an estimated 1,200 mL. The uterus is boggy despite fundal massage and an oxytocin infusion that is running. BP 158/102 mm Hg, HR 118. The placenta was delivered and looked complete. What do you do next?
Rubric
- +2Gives tranexamic acid 1 g IV over 10 minutes within 3 hours of birth (repeat once after 30 min if bleeding continues)
- +3States methylergonovine is contraindicated because of her preeclampsia/hypertension
- +3States carboprost should be avoided because of her asthma
- +2Gives misoprostol (about 600–1,000 mcg by any route) as the second-line uterotonic
- +1Performs bimanual massage and examines for lacerations and retained tissue
- +1Plans intrauterine balloon tamponade if bleeding continues
- +1Activates the massive transfusion protocol and checks fibrinogen
- -4Gives methylergonovine, or uses carboprost as the second-line uterotonic
Show answer
Reference answer This is postpartum hemorrhage from atony. Call for help, activate the hemorrhage/massive transfusion protocol, and start bimanual uterine massage while continuing oxytocin. Examine the genital tract for lacerations and the uterine cavity for retained tissue. Give tranexamic acid 1 g IV over 10 minutes (within 3 hours of birth), with a second 1 g dose if bleeding continues after 30 minutes. For the second-line uterotonic, methylergonovine is contraindicated because of her preeclampsia and hypertension, and carboprost (15-methyl PGF2α) should be avoided because of her severe asthma (bronchospasm). Give misoprostol (600–1,000 mcg, e.g. 800 mcg rectally or sublingually). If bleeding continues, place an intrauterine balloon tamponade and escalate to interventional radiology or surgery. Send fibrinogen and coagulation studies, and transfuse in balanced ratios.
Source ACOG Practice Bulletin No. 183: Postpartum Hemorrhage (2017); WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage (2017)
- HCR-008Short answerOncologyAdvanced
A 58-year-old man with metastatic melanoma received his third cycle of ipilimumab plus nivolumab 3 weeks ago. He was admitted 4 days ago with fatigue, headache and nausea. Admission labs, all drawn before any glucocorticoid: AST 412 U/L, ALT 520 U/L (ULN 40), bilirubin 1.1 mg/dL, INR 1.0; sodium 129 mEq/L, potassium 4.2 mEq/L, glucose 68 mg/dL; 8 AM cortisol 1.8 µg/dL, ACTH 5 pg/mL, TSH 0.3 mIU/L, free T4 0.5 ng/dL (low). Viral hepatitis serologies and liver imaging were negative; he takes no other drugs or alcohol. IV methylprednisolone 1 mg/kg/day was started on admission. Today AST is 398 U/L and ALT 505 U/L. He feels a little better; BP 112/70. What is going on, and what do you do now?
Rubric
- +3Recognizes steroid-refractory immune-mediated hepatitis after about 3 days and adds mycophenolate mofetil (about 500–1,000 mg twice daily) or azathioprine
- +2States infliximab is avoided for immune-mediated hepatitis because of hepatotoxicity
- +1Holds (or permanently discontinues) ipilimumab and nivolumab
- +2Diagnoses ipilimumab-induced hypophysitis with secondary adrenal insufficiency and central hypothyroidism
- +2Starts levothyroxine now that glucocorticoid cover is in place, and titrates it by free T4 rather than TSH
- +2Plans lifelong physiologic hydrocortisone after the high-dose taper because ACTH deficiency is usually permanent, with sick-day education
- -3Gives infliximab for the hepatitis
Show answer
Reference answer Two immune-related adverse events. First, grade 3 immune-mediated hepatitis (ALT > 5–20 × ULN) that has not improved after 3 days of methylprednisolone 1 mg/kg/day, so it is steroid-refractory: hold ipilimumab/nivolumab, continue (or increase to 2 mg/kg/day) methylprednisolone, and add mycophenolate mofetil (500–1,000 mg twice daily; azathioprine is an alternative); involve hepatology. Infliximab is avoided for immune-mediated hepatitis because of its own hepatotoxicity. Second, ipilimumab-induced hypophysitis with secondary adrenal insufficiency (low cortisol with low ACTH) and central hypothyroidism (low free T4 with an inappropriately low TSH). The high-dose glucocorticoid currently covers the adrenal insufficiency; now that he is on glucocorticoids, start levothyroxine and titrate it by free T4, not TSH. ACTH deficiency after ipilimumab is usually permanent, so when the hepatitis steroids are tapered he needs lifelong physiologic hydrocortisone (about 15–20 mg/day in divided doses) with stress-dose and sick-day education and a medical alert. Pituitary MRI is reasonable.
Source Schneider BJ et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (J Clin Oncol 2021)
- HCR-009Short answerCritical careAdvanced
A 72-year-old woman (58 kg) is in the ICU with septic shock from pyelonephritis; she has needed norepinephrine 0.3 mcg/kg/min for 6 hours. Creatinine 2.6 mg/dL (baseline 0.8), estimated creatinine clearance 18 mL/min, and she is oliguric. She is intubated and sedated, with a nasogastric tube; no kidney replacement therapy is planned today. Her chart lists a penicillin allergy: "rash as a child". She has atrial fibrillation (apixaban at home), epilepsy (levetiracetam 1,000 mg twice daily) and depression (sertraline 100 mg daily). The admitting resident wrote these orders: 1. Cefepime 2 g IV now, then renally adjusted dosing per pharmacy 2. Vancomycin 750 mg IV every 24 h, no loading dose 3. Levetiracetam 1,000 mg IV every 12 h 4. Apixaban held; enoxaparin 40 mg SC daily for VTE prophylaxis 5. Hydrocortisone 50 mg IV every 6 h 6. Pantoprazole 40 mg IV daily 7. Morphine 4 mg IV every 2 h as needed for pain 8. Insulin infusion titrated to glucose 80–110 mg/dL 9. Sertraline 100 mg daily via nasogastric tube Which orders would you change, and how? Which are fine as written?
Rubric
- +2Fixes vancomycin: adds a loading dose (20–35 mg/kg, about 1.25–2 g) with level/AUC-guided dosing, or stops it as unneeded for a urinary source without MRSA risk
- +2Reduces levetiracetam to 250–500 mg every 12 h for CrCl < 30 mL/min
- +2Reduces enoxaparin prophylaxis to 30 mg daily for CrCl < 30 mL/min (or switches to subcutaneous heparin)
- +2Changes the glucose target to 140–180 mg/dL
- +2Replaces morphine with fentanyl or hydromorphone because of kidney failure
- +2States a remote childhood rash is not a reason to avoid beta-lactams (keeps cefepime with renal dosing, or picks another beta-lactam because of neurotoxicity risk)
- -2Stops hydrocortisone as unnecessary
- -2Replaces cefepime with a non-beta-lactam (e.g., aztreonam or a fluoroquinolone) because of the penicillin label
Show answer
Reference answer Change: (2) if vancomycin is continued it needs a loading dose of 20–35 mg/kg actual body weight (about 1.25–2 g) regardless of kidney function, with subsequent doses guided by levels/AUC; stopping it is also reasonable for a urinary source without MRSA risk factors. (3) Levetiracetam at CrCl < 30 mL/min is 250–500 mg every 12 h. (4) Enoxaparin prophylaxis at CrCl < 30 mL/min is 30 mg daily (or use subcutaneous unfractionated heparin). (7) Morphine's active metabolites accumulate in kidney failure: use fentanyl or hydromorphone instead. (8) Intensive glucose targets increase hypoglycemia and mortality: target 140–180 mg/dL. Fine as written: (1) cefepime — a remote, non-severe childhood rash is not a reason to avoid a cephalosporin, and a full first dose followed by renal adjustment is correct (with monitoring for cefepime neurotoxicity; meropenem is a reasonable alternative given her epilepsy); (5) hydrocortisone 200 mg/day is suggested because she has needed norepinephrine ≥ 0.25 mcg/kg/min for at least 4 hours; (6) stress ulcer prophylaxis is appropriate in shock; (9) sertraline can continue.
Source Surviving Sepsis Campaign 2021; ASHP/IDSA/PIDS/SIDP Vancomycin Therapeutic Monitoring Consensus (2020); levetiracetam and enoxaparin US prescribing information; NICE-SUGAR (NEJM 2009) and ADA Standards of Care 2025 (inpatient glucose 140–180 mg/dL); AAAAI/ACAAI Drug Allergy Practice Parameter 2022
- HCR-010Short answerHematologyAdvanced
A 30-year-old man (75 kg) has severe hemophilia A with a high-titer factor VIII inhibitor and receives weekly emicizumab prophylaxis. He falls off his bike and develops a large, tense thigh hematoma; hemoglobin falls from 13.1 to 9.6 g/dL. His aPTT is 27 s (normal). In the past his bleeds were treated with FEIBA 75 U/kg every 12 hours, and a junior colleague suggests restarting that. What do you do?
Rubric
- +3States the normal aPTT reflects emicizumab interference and does not mean hemostasis is adequate
- +3Treats with recombinant factor VIIa (about 90 mcg/kg every 2 h until hemostasis) as the preferred bypassing agent
- +3Rejects the old FEIBA regimen; if aPCC is unavoidable limits it to an initial dose of 50 U/kg or less and no more than 100 U/kg/24 h, because of TMA and thrombosis with emicizumab
- +1Notes factor VIII concentrate is ineffective with a high-titer inhibitor
- +1Uses chromogenic assays with bovine reagents for FVIII activity or inhibitor testing
- +1Monitors for compartment syndrome and involves the hemophilia treatment center
- -4Gives aPCC with an initial dose above 50 U/kg or more than 100 U/kg in 24 h
Show answer
Reference answer The normal aPTT is an artifact: emicizumab bypasses the need for activated factor VIII in the intrinsic pathway and shortens or normalizes aPTT-based tests, so the aPTT and one-stage FVIII assays do not reflect his hemostatic protection, which is inadequate for a major bleed. Factor VIII concentrate will not work because of the high-titer inhibitor. The preferred bypassing agent on emicizumab is recombinant factor VIIa, 90 mcg/kg IV every 2 hours until hemostasis. Do not restart FEIBA at his old dose: with emicizumab, cumulative aPCC above 100 U/kg/24 h for 24 hours or more caused thrombotic microangiopathy and thrombosis; if aPCC is unavoidable, WFH/MASAC advise starting at no more than 50 U/kg and stay under 100 U/kg in 24 h, monitoring for TMA. Measure FVIII activity or inhibitor titer with chromogenic assays using bovine reagents. Continue emicizumab, involve the hemophilia treatment center, and watch for compartment syndrome.
Source Emicizumab (Hemlibra) US prescribing information, boxed warning and laboratory interference; WFH Guidelines for the Management of Hemophilia, 3rd edition (2020); NBDF MASAC recommendation on emicizumab and bypassing agents
- HCR-011Multiple choiceNeurologyAdvanced
A 70-year-old woman on hemodialysis for end-stage renal disease takes phenytoin 300 mg daily for epilepsy. She now has nystagmus, ataxia and slurred speech. Total phenytoin level 8.5 mcg/mL (therapeutic 10–20), albumin 2.2 g/dL. A free phenytoin level will take 3 days. Using the Sheiner–Tozer equation with its end-stage renal disease modification, what is the best interpretation and action?
- AThe level is subtherapeutic; give a 10 mg/kg loading dose and increase the maintenance dose
- BThe adjusted level is about 27 mcg/mL; hold phenytoin and send a free level to confirm
- CThe adjusted level is about 16 mcg/mL; continue the current dose and look for another cause
- DThe adjusted level is about 12 mcg/mL; continue the current dose
- ETotal levels cannot be interpreted in dialysis patients; switch to fosphenytoin at the same dose
Show answer
Answer B
Source Winter ME. Basic Clinical Pharmacokinetics, 5th ed. (Sheiner–Tozer albumin correction for phenytoin, with the end-stage renal disease modification); phenytoin US prescribing information
- HCR-012Short answerOncologyAdvanced
A 38-year-old man (75 kg, BSA 1.9 m²) with Burkitt lymphoma had hemolytic anemia two years ago after a course of dapsone. Twenty hours after starting chemotherapy: potassium 6.2 mEq/L, phosphate 8.9 mg/dL, calcium 6.6 mg/dL (albumin 4.0 g/dL), uric acid 13.8 mg/dL, creatinine 2.6 mg/dL (baseline 0.9). Urine output over the last 4 hours is 0.4 mL/kg/h. He is clinically euvolemic with no edema and clear lungs, and has no tetany or paresthesias; ECG shows peaked T waves with a normal QRS and QTc 450 ms. The night team has ordered rasburicase 0.2 mg/kg, sodium bicarbonate in his fluids and IV calcium gluconate to correct the calcium. What do you do?
Rubric
- +3Recognizes suspected G6PD deficiency from the dapsone hemolysis, cancels rasburicase, and uses allopurinol (renally adjusted) or febuxostat
- +2Gives IV hydration toward 2–3 L/m²/day as tolerated, without potassium or phosphate, monitoring for overload
- +2Stops the bicarbonate (no urine alkalinization) and says why
- +2Does not use calcium to correct the asymptomatic hypocalcemia because of calcium-phosphate precipitation (calcium, if any, only for the ECG change)
- +2Treats the hyperkalemia (insulin with dextrose, potassium binder) and gives a non-calcium phosphate binder
- +2Involves nephrology early for kidney replacement therapy
- -4Gives rasburicase before G6PD deficiency is excluded
Show answer
Reference answer This is laboratory and clinical TLS with oliguric AKI. Hemolysis after dapsone suggests G6PD deficiency: cancel rasburicase (severe hemolysis and methemoglobinemia) until G6PD status is known, and use allopurinol (dose-reduced for his kidney function) or febuxostat to stop further uric acid production. Give IV hydration toward 2–3 L/m²/day as tolerated, with fluids free of potassium and phosphate, watching closely for volume overload given the oliguria. Stop the bicarbonate: urine alkalinization promotes calcium phosphate precipitation. Do not correct the asymptomatic hypocalcemia with calcium, because with phosphate 8.9 mg/dL it precipitates calcium phosphate in the kidneys and tissues; the only role for IV calcium here is membrane stabilization for the hyperkalemic ECG change, at the lowest effective dose. Treat potassium with insulin and dextrose and a potassium binder, and give a non-calcium phosphate binder (e.g., sevelamer). Call nephrology now for early kidney replacement therapy.
Source Cairo MS, Coiffier B et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (Br J Haematol 2010); Jones GL et al. BCSH guidelines for TLS (Br J Haematol 2015); rasburicase US prescribing information
- HCR-013Short answerNephrologyAdvanced
A 58-year-old woman (50 kg) with alcohol use disorder and poor oral intake, taking hydrochlorothiazide, is admitted confused (no seizures). Sodium 108 mEq/L, potassium 2.6 mEq/L. She received one 100-mL bolus of 3% saline, then 1 L of 0.9% saline containing 80 mEq KCl over 6 hours; hydrochlorothiazide was stopped. At 6 hours her confusion is better and sodium is 117 mEq/L. Over the last 2 hours her urine output has been 450 mL/h with urine osmolality 90 mOsm/kg. Your unit follows the 2013 US expert panel recommendations. What now?
Rubric
- +2Identifies high risk for osmotic demyelination (alcohol use, hypokalemia, malnutrition)
- +2Uses the high-risk limit of 8 mEq/L per 24 h (goal 4–6) and states it is already exceeded
- +2Attributes the ongoing rise to a water diuresis (after thiazide withdrawal, volume repletion and/or restored solute intake)
- +3Re-lowers sodium with desmopressin (about 2–4 mcg IV/SC) plus D5W, aiming back to 116 mEq/L or less
- +1Notes that potassium replacement raises serum sodium and counts toward the correction
- +1Gives thiamine
- +1Rechecks sodium every 1–2 hours during re-lowering
- -3Continues 0.9% or hypertonic saline
Show answer
Reference answer She is at high risk of osmotic demyelination: alcohol use disorder, hypokalemia and malnutrition (the hyponatremia is also likely chronic). For high-risk patients the panel's goal is 4–6 mEq/L and the limit is 8 mEq/L in any 24 hours; she has already risen 9 mEq/L in 6 hours, so the limit is exceeded. The cause is a water diuresis (dilute urine at 450 mL/h) as the thiazide effect wears off and volume is restored, and the potassium replacement also raises serum sodium. Stop the saline. Re-lower the sodium: give desmopressin 2–4 mcg IV or SC and electrolyte-free water as D5W (for example 3 mL/kg/h) until sodium is back to no more than 8 above baseline (≤ 116 mEq/L), checking sodium every 1–2 hours. Continue potassium repletion cautiously, counting it toward the sodium rise. Give thiamine.
Source Verbalis JG et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations (Am J Med 2013)
- HCR-014Short answerMetabolic medicineAdvanced
A 24-year-old woman (55 kg, BSA 1.6 m²) is 5 days postpartum. Valproate was started 4 days ago for new-onset seizures. Since yesterday she has vomited, become confused and now is barely rousable (GCS 9). Ammonia 410 µmol/L, glucose 92 mg/dL, AST and ALT normal, INR 1.0, bilirubin normal, venous pH 7.48 with PaCO2 29 mm Hg, valproate level 68 mcg/mL. Head CT is normal. Her brother died at 5 days old of what the family calls "a metabolic illness". What is the likely diagnosis, and what is your management?
Rubric
- +2Suspects a urea cycle disorder (likely OTC deficiency) unmasked by postpartum catabolism and valproate, and sends plasma amino acids and urine orotic acid
- +2Stops valproate and stops protein intake temporarily (24–48 h)
- +2Gives high-calorie IV 10% dextrose (± lipid, insulin if hyperglycemic) to reverse catabolism
- +3Gives IV sodium phenylacetate/sodium benzoate (5.5 g/m² of each component, i.e. 55 mL/m² Ammonul, over 90–120 min, then the same per 24 h) with IV arginine
- +3Starts urgent hemodialysis (or high-flow CRRT) for coma with ammonia above 400 µmol/L
- +1Gives L-carnitine for the valproate exposure
- -3Treats it as hepatic encephalopathy with lactulose/rifaximin alone
Show answer
Reference answer Hyperammonemic coma with normal liver function, respiratory alkalosis and a family history of male neonatal death points to a urea cycle disorder, most likely heterozygous ornithine transcarbamylase (OTC) deficiency unmasked by postpartum catabolism and valproate. Send plasma amino acids (low citrulline, high glutamine) and urine orotic acid, but treat now. Stop valproate. Stop protein intake (for no more than 24–48 hours). Stop catabolism with high-calorie IV 10% dextrose (plus IV lipid, with insulin if hyperglycemic). Give IV sodium phenylacetate/sodium benzoate (5.5 g/m² of each component, i.e. 55 mL/m² of Ammonul, about 88 mL here, diluted in 10% dextrose) over 90–120 minutes, then the same dose over 24 hours, with IV arginine hydrochloride (about 200–250 mg/kg, roughly 11–14 g, over 90–120 minutes, then the same over 24 hours), both through a central line. With coma and ammonia above 400 µmol/L, start urgent hemodialysis (or high-flow CRRT) without waiting for the scavengers to work. L-carnitine is reasonable for the valproate exposure. Manage in ICU with a metabolic specialist and watch for cerebral edema. Lactulose and rifaximin, the hepatic encephalopathy treatment, do not address this.
Source Häberle J et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision (J Inherit Metab Dis 2019); sodium phenylacetate and sodium benzoate (Ammonul) US prescribing information
- HCR-015Short answerCritical careAdvanced
A 40-year-old man (80 kg) is burned at 14:00 when gasoline ignites at an outdoor barbecue. He arrives at your emergency department at 16:00, having received 1,000 mL of lactated Ringer's from paramedics. He has no inhalation injury. Burns: the whole anterior trunk has blistered, moist, painful partial-thickness burns; the entire right arm has white, leathery, insensate full-thickness burns all the way round; the anterior surface of the left leg has blistered partial-thickness burns; the face and neck are red and painful with no blisters. Your unit estimates burn size with the rule of nines and uses the Parkland formula (4 mL/kg/%TBSA, half in the first 8 hours). Write his fluid orders for the first 24 hours and say how you will adjust them.
Rubric
- +2Excludes the superficial (red, unblistered) face and neck burns, giving 36% TBSA
- +2Calculates 11,520 mL of lactated Ringer's for 24 h
- +2Times the first 5,760 mL from the burn at 14:00, not from arrival
- +2Subtracts the 1,000 mL prehospital fluid and gives the remaining 4,760 mL over 6 h (about 790–800 mL/h)
- +1Then gives 5,760 mL over 16 h (360 mL/h)
- +2Titrates to urine output of about 0.5 mL/kg/h (30–50 mL/h) rather than the formula
- +1Monitors the circumferential full-thickness arm for escharotomy
- -2Counts the superficial face and neck burns in the TBSA
Show answer
Reference answer By the rule of nines: anterior trunk 18% + whole right arm 9% + anterior left leg 9% = 36% TBSA. The red, unblistered face and neck are superficial (first-degree) burns and are not counted. Parkland: 4 × 80 × 36 = 11,520 mL of lactated Ringer's in 24 hours, half (5,760 mL) in the first 8 hours counted from the time of the burn (14:00), not from arrival. He has already had 1,000 mL, and 2 of the 8 hours have passed, so give 4,760 mL over the next 6 hours ≈ 790 mL/h until 22:00, then 5,760 mL over the following 16 hours = 360 mL/h. The formula is only a starting rate: titrate hourly to urine output of 0.5 mL/kg/h (about 30–50 mL/h) via a urinary catheter, increasing the rate if output is below target and reducing it if output is higher, to avoid over-resuscitation. The circumferential full-thickness arm burn needs hourly neurovascular checks and escharotomy if perfusion is threatened. He meets burn-center transfer criteria.
Source Parkland (Baxter) formula as the stated unit protocol (ABLS 2018 itself now starts adult thermal burns at 2 mL/kg/%TBSA); American Burn Association Advanced Burn Life Support (ABLS) Provider Manual 2018 (rule of nines, urine output targets, escharotomy)
- HCR-016Short answerHepatologyAdvanced
A 56-year-old man (70 kg) with alcohol-associated cirrhosis (Child-Pugh C) was admitted 6 days ago with hepatic encephalopathy, which improved on lactulose and rifaximin. His regular medicines are propranolol 40 mg twice daily for varices, furosemide 40 mg and spironolactone 100 mg daily, and he has been given ibuprofen as needed for back pain. Today he has abdominal pain and a temperature of 38.2 °C. BP 88/54 mm Hg, HR 96. Creatinine 2.0 mg/dL (1.0 on admission), BUN 38 mg/dL, bilirubin 4.6 mg/dL, sodium 128 mEq/L, SpO2 96%. Diagnostic paracentesis: ascitic neutrophils 680/µL, culture pending. What do you do?
Rubric
- +3Treats it as nosocomial SBP with broad-spectrum cover per local resistance (e.g., piperacillin–tazobactam or meropenem ± MRSA/VRE cover), not ceftriaxone alone
- +2Gives IV albumin 1.5 g/kg (about 105 g) at diagnosis and 1 g/kg (about 70 g) on day 3
- +2Holds or reduces propranolol because of hypotension/AKI, and stops the diuretics and ibuprofen
- +2Repeats paracentesis at 48 h, treating a neutrophil fall of less than 25% as treatment failure
- +1Plans terlipressin plus albumin for HRS-AKI only if creatinine fails to improve after 48 h and shock and nephrotoxins (the recent ibuprofen) are excluded as causes
- +1Plans long-term secondary SBP prophylaxis after treatment
- -3Uses ceftriaxone or cefotaxime alone
Show answer
Reference answer This is nosocomial spontaneous bacterial peritonitis (developing after more than 48 hours in hospital) with AKI. Nosocomial SBP needs broader empiric cover than ceftriaxone, according to local resistance: for example piperacillin–tazobactam or meropenem, adding vancomycin or daptomycin where MRSA/VRE are common. Give IV albumin 1.5 g/kg (105 g) within 6 hours of diagnosis and 1 g/kg (70 g) on day 3, because creatinine is > 1 mg/dL, BUN > 30 mg/dL and bilirubin > 4 mg/dL. Stop propranolol (systolic BP < 90 mm Hg, AKI), stop the diuretics and stop ibuprofen. Repeat paracentesis at 48 hours: a fall in ascitic neutrophils of < 25% means treatment failure. If creatinine does not improve after 48 hours of diuretic withdrawal and albumin (1 g/kg/day), and shock and nephrotoxins (the recent ibuprofen) are no longer plausible causes, treat as HRS-AKI with terlipressin plus albumin, checking oxygenation first (terlipressin is contraindicated with SpO2 < 90%). After recovery he needs long-term secondary prophylaxis (e.g., ciprofloxacin, chosen with the culture result in mind). With abdominal pain, keep secondary peritonitis in mind (Runyon criteria on the ascitic fluid).
Source Biggins SW et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD (Hepatology 2021); Baveno VII Consensus (J Hepatol 2022); terlipressin US prescribing information
- HCR-017Multiple choiceNeurologyAdvanced
A 45-year-old woman (70 kg) with generalized epilepsy has been seizure-free for years on valproate 1,000 mg twice daily (trough levels 70–90 mcg/mL). She is admitted with an ESBL-producing E. coli bloodstream infection from a pyelonephritis and is started on meropenem. By day 3 she is afebrile and hemodynamically stable, repeat blood cultures are negative and she is eating normally, but she has two generalized seizures; her total valproate level is 11 mcg/mL and she has been taking every dose. The isolate is also susceptible to ciprofloxacin and amikacin. Which is the best management?
- AGive a valproate IV loading dose of 40 mg/kg and increase the maintenance dose until the level is back in range
- BCheck a free valproate level, because hypoalbuminemia explains the low total level
- CSwitch meropenem to ertapenem, which does not interact with valproate
- DChange meropenem to a non-carbapenem active agent and give a different antiseizure medicine (e.g., levetiracetam) to cover until valproate levels recover
- EContinue meropenem and valproate unchanged and add lorazepam as needed for seizures
Show answer
Answer D
Source Valproate (Depakote/Depacon) US prescribing information, warning on interaction with carbapenems; meropenem US prescribing information; IDSA 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections (oral step-down for ESBL-E)
- HCR-018Short answerInfectious diseaseAdvanced
A 38-year-old man (64 kg) with HIV started bictegravir/emtricitabine/tenofovir alafenamide 2 weeks ago (CD4 62 cells/µL, viral load 210,000 copies/mL). He now has 3 weeks of cough, fever and night sweats; sputum Xpert MTB/RIF is positive with no rifampicin resistance detected. No neurological symptoms. ALT normal, creatinine clearance 95 mL/min. He receives no other medicines. How do you treat his tuberculosis, and what do you do about his HIV treatment?
Rubric
- +3Recognizes bictegravir is contraindicated with rifampin and switches to dolutegravir 50 mg twice daily (or efavirenz, or raltegravir 800 mg twice daily) with a TDF/emtricitabine backbone
- +2Continues antiretroviral therapy without interruption
- +2Treats with isoniazid, rifampin, pyrazinamide and ethambutol for 2 months, then isoniazid and rifampin for 4 months
- +1Gives pyridoxine with isoniazid
- +1Keeps dolutegravir twice daily until about 2 weeks after rifampin is stopped
- +1Gives Pneumocystis prophylaxis because CD4 is below 200
- -3Stops ART until TB treatment is finished
- -2Continues bictegravir with rifampin
Show answer
Reference answer Drug-susceptible pulmonary TB: daily isoniazid, rifampin, pyrazinamide and ethambutol for 2 months, then isoniazid and rifampin for 4 months (6 months total), with weight-based doses for 64 kg (isoniazid 300 mg, rifampin 600 mg, pyrazinamide about 1,500 mg, ethambutol about 1,200 mg), plus pyridoxine 25–50 mg daily with isoniazid. Rifampin is a strong inducer: bictegravir is contraindicated with rifampin and tenofovir alafenamide is not recommended with it. Do not stop ART. Switch to dolutegravir 50 mg twice daily (instead of once daily) with tenofovir disoproxil fumarate/emtricitabine; an efavirenz-based regimen is an alternative. Continue dolutegravir twice daily until 2 weeks after rifampin stops. He also needs Pneumocystis prophylaxis (CD4 < 200), and should be warned about TB-IRIS, which is likely with this low CD4.
Source DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (current), drug interaction tables for rifamycins; ATS/CDC/IDSA Treatment of Drug-Susceptible Tuberculosis (2016); bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) and dolutegravir US prescribing information
- HCR-019Short answerAnesthesiologyAdvanced
A 64-year-old woman (68 kg) receives an ultrasound-guided supraclavicular brachial plexus block with 30 mL of 0.5% bupivacaine. Two minutes later she becomes agitated, then has a generalized seizure. Shortly afterwards the monitor shows a wide-complex tachycardia at 180/min with a palpable pulse and BP 72/40 mm Hg. How do you manage her?
Rubric
- +3Gives 20% lipid emulsion about 1.5 mL/kg (about 100 mL; ideal or lean body weight acceptable) over 2–3 min, then an infusion of about 0.25 mL/kg/min
- +2Treats the seizure with a benzodiazepine (avoiding large propofol doses with cardiovascular instability)
- +3Prioritizes lipid; for the ventricular arrhythmia uses amiodarone (or synchronized cardioversion) and explicitly avoids lidocaine/procainamide
- +2If cardiac arrest occurs, reduces epinephrine to boluses of 1 mcg/kg or less
- +1Avoids vasopressin, calcium channel blockers and beta-blockers
- +1Alerts the bypass/ECMO team early and monitors for at least 4–6 hours after cardiovascular instability
- -4Gives lidocaine for the wide-complex tachycardia
Show answer
Reference answer This is local anesthetic systemic toxicity. Stop injecting, call for help, manage the airway with 100% oxygen and avoid hypoxia and acidosis. Treat the seizure with a benzodiazepine (avoid large propofol doses when the circulation is unstable). Give 20% lipid emulsion now: a bolus of 1.5 mL/kg over 2–3 minutes (about 100 mL), then an infusion of 0.25 mL/kg/min (about 17 mL/min); repeat the bolus and double the infusion to 0.5 mL/kg/min if she stays unstable, up to about 12 mL/kg. Lipid takes priority. For the ventricular arrhythmia, synchronized cardioversion is appropriate now that she is hypotensive (it may be refractory until lipid works), and amiodarone is the antiarrhythmic of choice; do not give lidocaine or procainamide (more sodium-channel blockade). Avoid calcium channel blockers, beta-blockers and vasopressin. If she arrests, start CPR and use small epinephrine doses (≤ 1 mcg/kg). Alert the cardiopulmonary bypass/ECMO team early, and monitor for at least 4–6 hours after a cardiovascular event.
Source ASRA Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017 (Neal JM et al., Reg Anesth Pain Med 2018) and the ASRA LAST checklist (2020)
- HCR-020Multiple choiceCardiologyAdvanced
An 81-year-old man (64 kg) with nonvalvular atrial fibrillation (CHA2DS2-VASc 4) is starting anticoagulation. Creatinine 1.3 mg/dL; Cockcroft–Gault creatinine clearance 41 mL/min. He takes diltiazem 240 mg daily for rate control and atorvastatin. Which apixaban regimen is correct?
- A2.5 mg twice daily, because he is over 80 and his creatinine clearance is below 50 mL/min
- B2.5 mg twice daily, because diltiazem inhibits CYP3A4
- C5 mg once daily
- D10 mg twice daily for 7 days, then 5 mg twice daily
- E5 mg twice daily
Show answer
Answer E
Source Apixaban (Eliquis) US prescribing information, dosage in nonvalvular atrial fibrillation and drug interactions